Kris Cameron Wood

Assistant Professor of Pharmacology & Cancer Biology

Appointments and Affiliations

• Assistant Professor of Pharmacology & Cancer Biology
• Core Faculty in Innovation & Entrepreneurship
• Member of the Duke Cancer Institute

Contact Information

• Email Address: kris.wood@duke.edu
• Websites:
  • Wood Lab

Education

• Ph.D. Massachusetts Institute of Technology, 2007
• B.S. University of Kentucky at Lexington, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

• BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
• BIOLOGY 728E: University Program in Genetics and Genomics Biological Solutions Module V
• CMB 710D: Cell & Molecular Biology Module IV
• CMB 710E: Cell & Molecular Biology Module V
• CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
• CMB 778E: University Program in Genetics and Genomics Biological Solutions Module V
• MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
• MGM 778E: University Program in Genetics and Genomics Biological Solutions Module V
• MOLCAN 818: Molecular Mechanisms of Oncogenesis
• PHARM 393: Research Independent Study
• PHARM 394: Research Independent Study
• PHARM 493: Research Independent Study
• PHARM 494: Research Independent Study
• PHARM 495: Research Independent Study
• PHARM 818: Molecular Mechanisms of Oncogenesis
• UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
• UPGEN 778E: University Program in Genetics and Genomics Biological Solutions Module V

In the News

• Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, 2019 | Pratt School of Engineering)
• From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
• Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
• Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | Duke Cancer Institute)
• The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog)
• Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)

Representative Publications

• Lin, KH; Rutter, JC; Xie, A; Pardieu, B; Winn, ET; Bello, RD; Forget, A; Itzykson, R; Ahn, Y-R; Dai, Z; Sobhan, RT; Anderson, GR; Singleton, KR; Decker, AE; Winter, PS; Locasale, JW; Crawford, L; Puissant, A; Wood, KC, Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer., Nat Genet (2020) [10.1038/s41588-020-0590-9] [abs].
• Wood, KC, Druggable Vulnerabilities in Therapy-Resistant Lung Cancers, Journal of Thoracic Oncology, vol 15 no. 2 (2020), pp. S6-S6 [abs].
• Wood, KC, Overcoming MCL-1-driven adaptive resistance to targeted therapies., Nature Communications, vol 11 no. 1 (2020) [10.1038/s41467-020-14392-z] [abs].
• Liberti, MV; Allen, AE; Ramesh, V; Dai, Z; Singleton, KR; Guo, Z; Liu, JO; Wood, KC; Locasale, JW, Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis., The Journal of Biological Chemistry, vol 295 no. 1 (2020), pp. 111-124 [10.1074/jbc.RA119.010903] [abs].
• Zhong, Z; Sepramaniam, S; Chew, XH; Wood, K; Lee, MA; Madan, B; Virshup, DM, PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers., Oncogene, vol 38 no. 40 (2019), pp. 6662-6677 [10.1038/s41388-019-0908-1] [abs].